Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 3933)

## LOAN FACILITIES - ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES

The Board announces that the Company, as borrower, entered into the Facility Agreement on 8 November 2019. The Facility Agreement imposes, among other matters, specific performance obligations on the controlling shareholders of the Company.

This announcement is made pursuant to Rule 13.18 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

The board of directors (the "**Board**") of The United Laboratories International Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that on 8 November 2019, the Company, as borrower, entered into a facility agreement (the "**Facility Agreement**") with, among others, Bank of Communications Co. Ltd. Hong Kong Branch, Fubon Bank (Hong Kong) Limited, Hang Seng Bank Limited and Taipei Fubon Commercial Bank Co., Ltd., as mandated lead arrangers and bookrunners, for the dual currency term loan facilities in the amount equivalent to up to HK\$2 billion. The loan under the facilities shall be repaid in instalments within a 36 months term from the date of the Facility Agreement.

The Agreement imposes that, among other matters, Mr. Tsoi Hoi Shan, Ms. Choy Siu Chit, Ms. Ning Kwai Chun and their family trusts (i) individually or collectively do not cease to be the single largest shareholder of the Company; (ii) individually or collectively hold at least 40% of the entire issued capital of the Company; and (iii) do not cease management control over the Company or the Group. Any breach of these obligations will result in the facilities being cancelled and the loans, together with accrued interest and all other amounts outstanding, will become payable within five business days.

The Company will continue to comply with the disclosure obligations under Rule 13.21 of the Listing Rules for so long as circumstance giving rise to the above obligation continue to exist.

On behalf of the Board **The United Laboratories International Holdings Limited Tsoi Hoi Shan** *Chairman* 

Hong Kong, 8 November 2019

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.